Hogan C, Lynn J, Gabel J, Lunney J, O’Mara A, Wilkinson A. 2000. A Statistical Profile of Decedents in the Medicare Program. Washington, D.C.: Medicare Payment Advisory Commission.
Iezzoni LI. The risk of adjustment. Journal of the American Medical Association 1997; 278(19):1600–1607.
Ingham JM. 1998. The epidemiology of cancer at the end stage of life. In Principles and Practice of Supportive Oncology, Berger A, Portenoy R, Weissman DE, eds. Philadelphia: Lippincott-Raven.
IOM (Institute of Medicine). 1997. Approaching Death: Improving Care at the End of Life. Field MJ, Cassel CK, eds. Washington, D.C.: National Academy Press.
IOM. 1999. Ensuring Quality Cancer Care. Hewitt M, Simone JV, eds. Washington, D.C.: National Academy Press.
Journal of the National Cancer Institute. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook. Journal of the National Cancer Institute Monograph 1998; 1924:1–28.
Kaskarelis IS, Minardos IA, Abatzis PP, Malagari KS, Vrachliotis TG, Natsika MK, et al. Percutaneous metallic self-expandable endoprostheses in biliary obstruction caused by metastatic cancer. Hepatogastroenterology 1996; 43:785–791.
Kidder D. The effects of hospice coverage on Medicare expenditures. Health Services Research 1992; 27:195–217.
Kosary C L, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK. 2000. SEER Cancer Statistics Review, 1973–1992: Tables and graphs, NIH Pub. No. 96–2789. Bethesda, MD: National Cancer Institute.
Lewin-VHI, Inc. 1995. An Analysis of the Cost Savings of the Medicare Hospice Benefit. Commissioned by the National Hospice and Palliative Care Organization.
Lubitz JD, Riley GF. Trends in Medicare payments in the last year of life. New England Journal of Medicine 1993; 328:1092–1096.
Lynn J, Harrell F, Cohn F, et al. Prognoses of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. New Horizons 1997; 5(1): 56–61.
McEwan AJ, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun 1994; 15:499–504.
Mor V, Masterson-Allen S. A comparison of hospice vs conventional care of the terminally ill cancer patient. Oncology 1990; 4:85–91.
National Hospice and Palliative Care Organization. 2001. http://www.NHPCO.org/facts.htm
Neymark N, Adriaenssen I. The costs of managing patients with advanced colorectal cancer in 10 different European centres. European Journal of Cancer 1999; 35:1789–1795.
Peters WR, Dansey RD, Klein JL, Baynes RD. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000; 5:1– 13.
Polednak Ap, Shevchenko Ip. Hospital charges for terminal care of cancer patients dying before age 65. Journal of Health Care Finance 1998; 25(1)26–34.
President’s Cancer Panel. 1998. Cancer Care Issues in the United States: Quality of Care, Quality of Life. Bethesda, MD: National Cancer Institute, 1999. (http://deainfo.nci.nih.gov/ADVISORY/pcp/reports/index.htm)
Pritchard RS, Fisher ES, Teno JM, et al. Influence of patient preferences and local health system characteristics on the place of death. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Risks and Outcomes of Treatment. Journal of the American Geriatrics Society 1998; 46(10):1242–1250.